AbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
AbbVie (ABBV) Climbs on Market Open, Up 2.4%
February 10, 2020 9:41 AM ESTAbbVie (NYSE: ABBV) Climbs on Market Open, Up 2.4%
... MoreAbbvie (ABBV) PT Raised to $97 at Piper Sandler
February 7, 2020 1:23 PM ESTPiper Sandler analyst Christopher Raymond raised the price target on Abbvie (NYSE: ABBV) to $97.00 (from $95.00) while maintaining a Overweight rating following results.
... MoreAbbVie (ABBV) Sees Strong Gains Post-EPS
February 7, 2020 12:39 PM ESTAbbVie (NYSE: ABBV) seeing strong gains following results this morning. Shares up 5.5%.
... MoreAbbVie (ABBV) Tops Q4 EPS by 2c, FY20 EPS Guidance Beats
February 7, 2020 7:44 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $2.21, $0.02 better than the analyst estimate of $2.19. Revenue for the quarter came in at $8.7 billion versus the consensus estimate of $8.7 billion.
GUIDANCE:
AbbVie sees FY2020 EPS of $9.61-$9.71, versus the consensus of... More
